Please provide your email address to receive an email when new articles are posted on . A 2.5 mg/mL dose of triamcinolone acetonide showed equally as efficacious treatment for nail psoriasis vs.

Please provide your email address to receive an email when new articles are posted on . Steven Yeh, MD, of Truhlsen Eye Institute, University of Nebraska Medical Center, said by 4 weeks, patients with ...

BURLINGTON, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy ...

Hikma is offering triamcinolone acetonide injectable suspension in a 40mg/ml dose. The product is indicated for various inflammatory, autoimmune, hormonal and other conditions where a corticosteroid ...

Xipere approval was based on data from the phase 3 PEACHTREE trial, which included 160 patients with macular edema associated with anterior-, intermediate-, posterior-, or pan-uveitis. Xipere ® ...

Removal of language which stated that ZILRETTA was “not intended for repeat administration.” The updated label states that the “efficacy and safety of repeat administration of ZILRETTA have not been ...

To evaluate the clinical and visual outcome of an intravitreal injection of triamcinolone in patients with diabetic macular oedema refractory to laser treatment. The average duration of macular oedema ...

Recently approved, non-opioid therapy now available for the management of osteoarthritis knee pain Launch of ZILRETTA commences with full complement of field sales personnel deployed across the U.S.

To report the clinical outcome of a patient who received high-dose intravitreal triamcinolone acetonide as treatment for severe macular oedema secondary to adult Coat's syndrome. This case reports the ...

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced ...

Pooled analysis published in Pain and Therapy indicated that the number of rescue medication tablets used per day through Week 24 was significantly less for ZILRETTA versus placebo and triamcinolone ...